XFOR Key Statistics, Chart & Performance
The current stock price of XFOR is 4 USD. In the past month the price increased by 2.83%. In the past year, price decreased by -76.61%.
XFOR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About XFOR
Company Profile
X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The company is headquartered in Boston, Massachusetts and currently employs 143 full-time employees. The company went IPO on 2017-11-16. The firm is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. The company has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). The company has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Company Info
X4 PHARMACEUTICALS INC
61 North Beacon Street, 4th Floor
Boston MASSACHUSETTS 02134 US
CEO: Paula Ragan
Employees: 143
Phone: 18575298300
X4 PHARMACEUTICALS INC / XFOR FAQ
What does X4 PHARMACEUTICALS INC do?
X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The company is headquartered in Boston, Massachusetts and currently employs 143 full-time employees. The company went IPO on 2017-11-16. The firm is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. The company has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). The company has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
What is the current price of XFOR stock?
The current stock price of XFOR is 4 USD. The price decreased by -0.99% in the last trading session.
Does XFOR stock pay dividends?
XFOR does not pay a dividend.
What is the ChartMill rating of X4 PHARMACEUTICALS INC stock?
XFOR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for X4 PHARMACEUTICALS INC?
X4 PHARMACEUTICALS INC (XFOR) has a market capitalization of 349.76M USD. This makes XFOR a Small Cap stock.
What is the ownership structure of X4 PHARMACEUTICALS INC (XFOR)?
You can find the ownership structure of X4 PHARMACEUTICALS INC (XFOR) on the Ownership tab.
XFOR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to XFOR. When comparing the yearly performance of all stocks, XFOR is a bad performer in the overall market: 87.59% of all stocks are doing better.
XFOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XFOR. XFOR may be in some trouble as it scores bad on both profitability and health.
XFOR Financial Highlights
Over the last trailing twelve months XFOR reported a non-GAAP Earnings per Share(EPS) of -10.12. The EPS increased by 44.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.14% | ||
| ROE | -154.33% | ||
| Debt/Equity | 1.23 |
XFOR Forecast & Estimates
10 analysts have analysed XFOR and the average price target is 8.16 USD. This implies a price increase of 104% is expected in the next year compared to the current price of 4.
For the next year, analysts expect an EPS growth of 86.91% and a revenue growth 1476.4% for XFOR